Literature DB >> 19043449

The genetics of the p53 pathway, apoptosis and cancer therapy.

Alexei Vazquez1, Elisabeth E Bond, Arnold J Levine, Gareth L Bond.   

Abstract

The p53 pathway has been shown to mediate cellular stress responses; p53 can initiate DNA repair, cell-cycle arrest, senescence and, importantly, apoptosis. These responses have been implicated in an individual's ability to suppress tumour formation and to respond to many types of cancer therapy. Here we focus on how best to use knowledge of this pathway to tailor current therapies and develop novel ones. Studies of the genetics of p53 pathway components - in particular p53 itself and its negative regulator MDM2 - in cancer cells has proven useful in the development of targeted therapies. Furthermore, inherited single nucleotide polymorphisms in p53 pathway genes could serve a similar purpose.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043449     DOI: 10.1038/nrd2656

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  238 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  Janus-faces of NME-oncoprotein interactions.

Authors:  Nikolina Vlatković; Shie-Hong Chang; Mark T Boyd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-01       Impact factor: 3.000

3.  Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.

Authors:  Rajan Gogna; Esha Madan; Periannan Kuppusamy; Uttam Pati
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

4.  Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Authors:  Taeyoung Koo; Il-Kyu Choi; Minjung Kim; Jung-Sun Lee; Eonju Oh; Jungho Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2012-02-21       Impact factor: 5.695

Review 5.  Mechanisms of non-apoptotic programmed cell death in diabetes and heart failure.

Authors:  Gerald W Dorn
Journal:  Cell Cycle       Date:  2010-09-07       Impact factor: 4.534

6.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

7.  Nutlin's two roads toward apoptosis.

Authors:  Qi Zhang; Hua Lu
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

8.  Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

9.  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.

Authors:  Maral Jamshidi; Marjanka K Schmidt; Thilo Dörk; Montserrat Garcia-Closas; Tuomas Heikkinen; Sten Cornelissen; Alexandra J van den Broek; Peter Schürmann; Andreas Meyer; Tjoung-Won Park-Simon; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Garrett Teoh Hor Keong; Astrid Irwanto; Marko Laakso; Sampsa Hautaniemi; Kristiina Aittomäki; Carl Blomqvist; Jianjun Liu; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

10.  Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

Authors:  Linfeng Zheng; Yuping Zhu; Lei Lei; Wenyong Sun; Guoping Cheng; Shifeng Yang
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.